![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
Quantum Si Inc | NASDAQ:QSI | NASDAQ | Common Stock |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
-0.10 | -9.52% | 0.95 | 0.93 | 0.9459 | 1.0399 | 0.9342 | 1.03 | 1,286,098 | 23:08:34 |
Quantum-Si Incorporated (NASDAQ: QSI):
WHAT: Esteemed scientist Christopher Mason, Ph.D., of Weill Cornell Medicine, is set to discuss his Two Frontiers Project during an exclusive webinar hosted by GenomeWeb. Dr. Mason will also reveal his plans for using Quantum-Si’s benchtop protein sequencer, Platinum® to expand his multiomic research on extremophiles and what is needed for human survival in extreme environments.
WHY: Dr. Mason recently remarked, “To better understand disease and health, we must not only look at nucleic acids, but also other molecules and pivotal proteins. In recent years, the field of proteomics has surged forward. We are now experiencing a remarkable acceleration with advancements in protein sequencing, revealing new biology and post-translational modifications.”
WHO: The webinar will feature:
WHEN: The webinar, titled “Characterizing Far-Flung Extremophiles with Next-Generation Protein Sequencing™,” will take place on Wednesday, February 28, at 11:00 a.m. ET.
WHERE: Hosted online by GenomeWeb. Reserve your spot today: https://event.on24.com/wcc/r/4461798/062AF09F1284EB44601D82D2A32B9869?partnerref=QSI
About Quantum-Si Incorporated
Quantum-Si, The Protein Sequencing Company™, is focused on revolutionizing the growing field of proteomics. The Company’s suite of technologies is powered by a first-of-its-kind semiconductor chip designed to enable next-generation single-molecule protein sequencing and digitize proteomic research in order to advance drug discovery and diagnostics beyond what has been possible with DNA sequencing. Learn more at quantum-si.com or follow us on LinkedIn or X.
About Christopher Mason, Ph.D.
Christopher Mason, Ph.D., is a Professor of Genomics, Physiology, and Biophysics at Weill Cornell Medicine and the director of the WorldQuant Initiative for Quantitative Prediction. With over 300 peer-reviewed papers, five patents, and the foundation of numerous biotechnology companies and non-profits, Dr. Mason is a leading figure in genomics and predictive algorithms for medicine. He is also the author of “The Next 500 Years: Engineering Life to Reach New Worlds.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20240227306348/en/
Investor Relations Jeff Keyes, Chief Financial Officer ir@quantum-si.com
Media Relations Katherine Atkinson, SVP of Commercial Marketing media@quantum-si.com
1 Year Quantum Si Chart |
1 Month Quantum Si Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions